Summary
The innovation of the biohybrid and biodegradable nanovaccines to be taken to proof-of-concept lies in the combination of different parts of the nanovaccine. A biohybrid and biodegradable nanovaccine shows potential to: (i) enhance cancer treatment efficacy; (ii) to be universally applicable to all cancers, regardless of the tumour in question; (iii) prolonging the survival rate of cancer patients; (iv) increase the amount of complete tumor remissions; and (v) boost of tumor-specific immune responses. This will allow in the future towards a personalized patient cancer therapy/treatment. More importantly, the applicability of biohybrid and biodegradable nanovaccines extends beyond the cancer treatment, as it can be applied for other type of diseases.
Unfold all
/
Fold all
More information & hyperlinks
| Web resources: | https://cordis.europa.eu/project/id/825020 |
| Start date: | 01-01-2019 |
| End date: | 30-06-2020 |
| Total budget - Public funding: | 150 000,00 Euro - 150 000,00 Euro |
Cordis data
Original description
The innovation of the biohybrid and biodegradable nanovaccines to be taken to proof-of-concept lies in the combination of different parts of the nanovaccine. A biohybrid and biodegradable nanovaccine shows potential to: (i) enhance cancer treatment efficacy; (ii) to be universally applicable to all cancers, regardless of the tumour in question; (iii) prolonging the survival rate of cancer patients; (iv) increase the amount of complete tumor remissions; and (v) boost of tumor-specific immune responses. This will allow in the future towards a personalized patient cancer therapy/treatment. More importantly, the applicability of biohybrid and biodegradable nanovaccines extends beyond the cancer treatment, as it can be applied for other type of diseases.Status
CLOSEDCall topic
ERC-2018-PoCUpdate Date
27-04-2024
Images
No images available.
Geographical location(s)
